FRM
CLDX icon

Fox Run Management’s Celldex Therapeutics CLDX Stock Holding History

Fox Run Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,146
Closed -$390K – 956
2025
Q2 		$390K Sell
19,146
-13,524
-41% -$263K 0.06% 559
2025
Q1 		$593K Buy
32,670
+9,380
+40% +$210K 0.09% 414
2024
Q4 		$589K Buy
23,290
+13,966
+150% +$379K 0.11% 382
2024
Q3 		$317K Buy
+9,324
New +$355K 0.07% 521
2024
Q2 		– Sell
-4,824
Closed -$202K – 810
2024
Q1 		$202K Sell
4,824
-6,425
-57% -$264K 0.04% 632
2023
Q4 		$446K Buy
+11,249
New +$331K 0.11% 346

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fox Run Management's CLDX Position: Q3 2025 in Review

Fox Run Management sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 19,146 shares — an estimated $390K sold.

Fox Run Management first reported a position in CLDX in Q4 2023 and held it in 6 quarters. The position peaked at $593K in Q1 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Fox Run Management reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fox Run Management sold 19,146 Celldex Therapeutics shares in Q3 2025, an estimated $390K.
  • Fox Run Management first reported a position in Celldex Therapeutics in Q4 2023 and held it in 6 quarters.
  • Fox Run Management's Celldex Therapeutics position peaked at $593K in Q1 2025.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.